Kornimate/medical-research-clean huggingface dataset:
long pulse 1064 nm nd:yag laser in the treatment of erythematotelangiectatic rosacea and other erythematous telangiectatic facial conditions

Conditions: Rosacea, Erythematotelangiectatic

Summary: the goal of this clinical study is to assess the effectiveness of nd:yag laser 1064 nm in the long pulse mode in the treatment of signs of rosacea including the erythema of the face and telangiectasia. the used parameter of this laser was of very low energy (spot size: 5mm, fluence: 4.07 j/cm2, energy: 800 millijoules (mj) and frequency: 5 hz. about 2-3 passes performed in each treatment session. up to four sessions were performed for each patient with 2 weeks interval) and also its was expected to have minimal adverse effects.


Eligibility criteria:
inclusion criteria: * patient with rosacea (erythemato-telangiectatic type) exclusion criteria: * other clinical types of rosacea * pregnancy and lactation in females * history of malignancies * history of photosensitivity * history of any other modalities of treatment of rosacea over last 6 months

Keywords: nd:yag laser
tdm of gentamicin and vancomycin, in neonates, using dried blood spot sampling.

Conditions: Blood Sample for Routine Care; Term or Premature Newborns (28 to 44 Amenorrhea Weeks); Gentamicin and/or Vancomycin

Summary: gentamicin and vancomycin, widely used in neonatology, are antibiotics with a narrow therapeutic index and a risk of nephrotoxicity and ototoxicity. for these drugs, therapeutic drug monitoring (tdm) is required, to optimize the efficacy and tolerance of these antibiotics. in newborns, the tdm of these antibiotics is really available, because of physiological features, such as renal elimination and hepatic metabolism which are both very dependent on age and maturation. thus, in newborn, there is a large interindividual variability of pharmacokinetic parameters, making the dosage adjustment of antibiotics very difficult. unfortunately, because of a limited blood mass, the tdm of these antibiotics is very rarely practiced in these children. the introduction of a died blood spot (dbs), which uses only a single drop of blood (\<50 μl) preserved in dried form, thus makes it possible to reduce the blood volume taken and avoid the venous intrusion. the dosage needs the use of liquid chromatography coupled with tandem mass spectrometry (lc-msms), the only sensitive technique to work with such a low blood volume. we therefore wish to develop this approach coupling dbs and lc-msms, in neonatology, to evaluate the concentration of these nephrotoxic antibiotics (gentamicin and vancomycin), as tdm. the blood concentrations of the antibiotic, per 100 new-born term or premature (50 gentamicin, 50 vancomycin), are compared to the physiological state of the child (premature or not, intrauterine growth retardation or not), its hemodynamic status (shock or not) and its efficacy / toxicity, evaluated by the clinician using a questionnaire. the use of this new sampling method, as an alternative to conventional blood sampling, makes it possible to better monitor the concentrations of gentamicin and vancomycin in neonatalogy, thus reducing the risk of toxicity of these antibiotics.


Eligibility criteria:
inclusion criteria: * term or premature newborns who receive one or two antibiotics (gentamicin, vancomycin) and who could benefit from pharmacological dosages of these drugs * premature from age 28 amenorrhea weeks * newborns up to 44 weeks corrected age * newborns at term / premature having a blood sample provided for routine care (capillary or venous sampling for blood glucose, blood gas, hemoglobinemia, sodium, potassium, lactate, bilirubin) exclusion criteria: * premature before age 28 amenorrhea weeks corrected * newborns over 44 weeks of age corrected * hemostasis disorders * hemoglobinopathies * hearing or kidney malformation * absence of blood sampling as part of the routine care
complementary and alternative medicine on mental health in breast cancer patients

Conditions: Breast Cancer

Summary: during cancer treatment, several patient experience substantial psychological distress, mainly depression and anxiety, which can persist over years after completion of treatment. complementary and alternative medicine (cam) has been in use among cancer patients for a long time and several types of cam that are practiced in various parts of the world. however, the effectiveness of different cam therapies on mental health is still limited. therefore, the investigators want to assess the effectiveness of complementary and alternative medicine (cam) (dance/movement therapy, art therapy, music therapy, bibliotherapy and physical activity) on mental health of cancer patients as well as their caregiver

during cancer treatment, several patient experience substantial psychological distress, mainly depression and anxiety, which can persist over years after completion of treatment. these psychological impairments can aggravate symptom burden and can seriously affect health-related quality of life. likewise, the diagnosis of cancer has not only a significant impact on the affected patients, but also on their families, and may cause emotional responses of shock, doubt, anxiety, and depression. complementary and alternative medicine (cam) has been in use among cancer patients for a long time and several types of cam that are practiced in various parts of the world. in the general among lithuanian adult population, the use of cam begins to seem common and the country claim for guidelines researches and to test the effectiveness of this practice to support the use of some cam therapies on mental health of patients as well as their families. in the st. francis oncology center in klaipeda some cam have been applied aimed to increase the recovery and quality of life in the patients and their families. the effectiveness of different cam therapies (dance/movement therapy, art therapy, music therapy, bibliotherapy and physical activity ) on mental health and recovery of cancer patients as well as on caregiving experiences and mental health of partners of cancer patients, it will be of great value to improve and provide a more effective service and the quality of caring in this patient as well as the continuing work of the francis oncology center in klaipeda and partners, with more higher scientific excellence and quality . objectives · to assess the effectiveness of complementary and alternative medicine (cam) (dance/movement therapy, art therapy, music therapy, bibliotherapy and physical activity) on mental health of cancer patients as well as their caregiver.

Eligibility criteria:
inclusion criteria: - all adult woman with breast cancer diagnoses and their primary family caregiver exclusion criteria: * insufficient physical capacity * severe mental disorder * inability ti give informed consent
safety and immunogenicity of two doses of a tetravalent influenza vaccine in adults aged 18 years and above

Conditions: Influenza

Summary: evaluate the immune response and reactogenicity of h5n1 vaccination in adults aged 18 years and above (as part of a tetravalent vaccine)


Eligibility criteria:
inclusion criteria: * healthy subjects (aged 18 years and above) who have signed an informed consent form exclusion criteria: * any acute or chronic illness * receipt of seasonal influenza vaccine for the current season 2007/2008 * known or suspected impairment/alteration of immune function * receipt of another vaccine within 3 weeks prior to visit 1 or planned vaccination within 3 weeks following the last study vaccination * any serious disease * hypersensitivity to eggs, chicken protein, chicken feathers, influenza viral protein,neomycin or kanamycin or any other component of the study vaccine * receipt of blood, blood products or immunoglobulins 3 months prior to vaccination

Keywords: avian flu seasonal influenza vaccine influenza vaccine prepandemic vaccine virus strain with the potential to cause pandemic tetravalent vaccine prophylaxis of influenza
pulmonary vein isolation (pvi) combined with renal denervation (rdn) in atrial fibrillation (af) and hypertension (htn)

Conditions: AF - Atrial Fibrillation; HTN-Hypertension

Summary: the close relationship between the increase of sympathetic tension, af, and htn cannot be ignored. in addition, the significant failure rate of pvi (20-50%) in the treatment of af makes it very necessary to explore the effect of rdn on af. therefore, this study aims to compare the effects and safety of pvi alone and pvi combined with rdn with af combined with htn, which will open a new chapter for pvi combined with rdn in the treatment of af.


Eligibility criteria:
inclusion criteria: * 18\<age\<75years * clinic blood pressure≥140/90mmhg or 24-hour ambulatory blood pressure monitoring average blood pressure ≥135/85mmhg * ecg diagnosis of atrial fibrillation ; * who signed informed consent and were approved by the ethics committee of the first affiliated hospital of xiamen university. exclusion criteria: * pregnant women or lactating patients; * patients who were unsuitable for ablation before surgery （unilateral or bilateral renal artery shape and structure were found： renal artery stenosis exceeding 50%, renal aneurysm, previous renal artery interventional surgery, renal artery malformation, renal artery diameter \< 4mm or length of treatable segment \< 20mm） * patients who only have one kidney or have a history of kidney transplantation * patients with a history of renal arterial intervention or renal denervation * identified secondary hypertension or pseudo hypertension except for renal parenchymal hypertension; * malignant tumors or end-stage diseases; * severe peripheral vascular disease, abdominal aortic aneurysm * whose left atrium is larger than 55mm * obvious bleeding tendency and blood system diseases; * severe peripheral vascular disease, abdominal aortic aneurysm; * a history of the acute coronary syndrome within two weeks; * acute or severe systemic infection; * drug or alcohol dependence or refusal to sign informed consent. * other conditions that are not suitable for pvi and rdn

Keywords: pulmonary vein isolation (pvi) renal denervation (rdn) atrial fibrillation (af) hypertension (htn)
vaccination against influenza in autoimmune diseases

Conditions: Autoimmune Diseases

Summary: the project is to evaluate immunogenicity, efficacy and tolerance of vaccination against influenza (seasonal and h1n1) in patients affected with systemic and autoimmune diseases.

this prospective study concentrates on patients with vasculitis, systemic sclerosis, sjögren's syndrome, systemic lupus erythematosus and other connective tissue diseases. patients responding to the inclusion criteria, will receive vaccine against seasonal influenza then, 3 weeks later, vaccine against h1n1 influenza. according to the results of ongoing trials a second injection of h1n1 vaccine has been scheduled 3 weeks later. at each consultation a blood sample will be taken to evaluate immunogenicity of vaccination. two additional consultations have been scheduled: one month after the last vaccine administration and at 6 month, in order to evaluate the occurrence of late side effects.

Eligibility criteria:
inclusion criteria: * adult patients presenting autoimmune and systemic diseases, * treating or not with steroids, and/or immunosuppressants and/or biotherapies, especially vasculitis, scleroderma, sjogren's syndrome and systemic lupus (main groups) exclusion criteria: * absence of informed consent * disease which did not responded to the above criteria * active infection at time of vaccination * hiv infection * history of guillain-barre syndrome * allergy to one component of the vaccine

Keywords: influenza autoimmune diseases vaccination h1n1
single injection of dexamethasone for acute bronchiolitis in young children

Conditions: Bronchiolitis, Viral

Summary: the purpose of this study was to determine whether a single intramuscular injection of dexamethasone decreased the duration of symptoms of acute bronchiolitis in young children.

acute bronchiolitis is an infection of the lower respiratory tract causing inflammation of the small airways, leading to bronchiolar obstruction. corticosteroids are frequently prescribed as anti-inflammatory drugs. the usefulness of corticosteroids for this disease remains controversial, despite many randomized controlled trials (rcts). recently, a meta-analysis and systemic review showed significant improvement in clinical symptoms, length of hospital stay and duration of symptoms in children with this disease after treatment with various regimens of systemic corticosteroids. dexamethasone is a long acting corticosteroid with biologic half-life ranging from 36-72 hours. a single dose of dexamethasone has been the standard recommendation for the treatment of croup which has a similar pathophysiology without evidence of adverse effects. furthermore, there is no previous report of this single dosage form of dexamethasone for the treatment of acute bronchiolitis in young children.

Eligibility criteria:
inclusion criteria: * aged 4 weeks - 24 months * has the first episode of wheezing within 7 days * has evidence of viral infection * requires hospital admission; criteria for admission include one of the following: age \ 60 breaths/minute for age \ or equal to 12 months; oxygen saturation in room air \< 95% and apathy or refuses feeding. exclusion criteria: * initial admission to intensive care unit * initial requirement for endotracheal intubation or mechanical ventilation * a previous history of intubation * a known history of asthma or response to the first dose of beta2 agonist nebulization * a history of prematurity * a history of bronchopulmonary dysplasia or chronic lung disease * underlying congenital heart disease or immunodeficiency * receives treatment of any form of corticosteroids within 2 weeks * has contraindication to corticosteroid treatment

Keywords: bronchiolitis wheezing dexamethasone young children
cyclosporine in patients with moderate covid-19

Conditions: COVID-19

Summary: phase 1 safety study to determine the tolerability, clinical effects, and changes in laboratory parameters of short course oral or iv cyclosporine (csa) administration in patients with covid-19 disease requiring oxygen supplementation but not requiring ventilator support.

our overall hypothesis is that csa is safe in this patient population and that it will have antiviral and anti-cytokine effects as measured in laboratory tests. the initial dose will be 9 mg/kg/day oral divided q12h or 3 mg/kg/day by continuous iv infusion. oral administration is generally preferred, however iv administration can be used if oral administration is not feasible or cannot be tolerated, or at the physician-investigator's clinical discretion. the dose will be adjusted to target a trough level of 200 to 300 ng/ml, which is in alignment with common clinical practice. the planned duration of csa treatment is up to 14 days, with planned discontinuation upon discharge from the hospital. dose reduction of 25% to 50% can be made for patients who experience adverse events such as hypertension or serum creatinine elevation. the end of study will be study day 30 for those patients who have been discharged from the hospital. if the patient remains in the hospital, the subject will still complete the end of study visit at day 30 as planned, but will continue to be followed until date of discharge.

Eligibility criteria:
inclusion criteria: 1. provision of signed and dated informed consent form 2. stated willingness to comply with all study procedures and availability for the duration of the study 3. male or female, aged \>18. 4. admitted to hospital with laboratory confirmation of sars-cov-2 infection. 5. estimated creatinine clearance \>50 ml/min using standard cockcroft-gault formula. exclusion criteria: 1. are admitted to the icu at time of enrollment. 2. have an active uncontrolled infection with a non-covid-19 agent. 3. have an active malignancy, not including non-melanoma skin cancer, superficial cervical or bladder cancer, mgus, or prostate cancer with psa \<1.0. 4. are on chronic immune suppressive medications, including 5. corticosteroid therapy at a prednisone equivalent dose of 10 mg per day or higher; therapy with calcineurin inhibitors or mtor inhibitors. 6. are pregnant 7. are lactating 8. have a known allergic reaction to components of the csa or its diluents. 9. are receiving investigational vaccine for sars-cov-2.
improving adherence to colonoscopy through teams and technology

Conditions: Colon Cancer; Cancer Colorectal; Colorectal Cancer

Summary: complete and timely colonoscopy after an abnormal stool-based colorectal cancer screening test results in early detection, cancer prevention, and reduction in mortality, but follow-up in safety-net health systems occurs in less than 50% at 6 months. the proposal will implement multi-level approach consisting of a stepped-wedge clinic-level intervention of team-based best practices co-developed with primary and specialty care, a patient-level technology intervention to provide enhanced instructions and navigation to complete diagnostic colonoscopy, and a mixed methods evaluation to explore multi-level factors contributing to intervention outcomes. developing a solution to this high-risk and diverse population has the potential to translate to other health systems, support patient self-management, and address other patient conditions.

follow-up colonoscopy after abnormal stool-based colorectal cancer screening (e.g., fecal immunochemical test (fit)) results in early detection of colorectal cancer (crc), prevention of crc, and reduction in crc mortality. fit is a commonly utilized screening test that can be performed at home, is inexpensive, scalable, and often adopted in health systems where colonoscopy resources are scarce. despite evidence that timely colonoscopy is necessary after an abnormal fit result, completion of colonoscopy occurs in less than 50% of patients at 6 months and varies significantly by clinic and health systems. in addition to understanding the meaning of an abnormal fit, three care transitions must occur smoothly for the patient: colonoscopy referral, scheduling, and attendance. however, multilevel factors influence missed follow-up, and multilevel solutions are needed along the care continuum to address clinic-, provider-, and patient-level factors that impair or delay colonoscopy completion. improving adherence to colonoscopy through teams and technology (impactt), proposes to close gaps and reduce disparities in crc screening by improving the completion of diagnostic colonoscopy following abnormal fit in vulnerable populations using a multilevel approach consisting of interventions at the clinic-, provider- and patient-level. the specific aims are 1) to evaluate the effect of a clinic-level intervention targeting primary care providers and staff to adopt "best practices" to support colonoscopy completion in patients with abnormal fit results, 2) to determine the effect of a patient-level technology intervention with enhanced instructions and navigation for patients with abnormal fit to complete a diagnostic colonoscopy, and 3) to explore the multilevel implementation factors contributing to intervention outcomes using mixed methods.

Eligibility criteria:
inclusion criteria: * patients with abnormal fit result * patients ages 18 years or older * english, spanish, or cantonese speaking exclusion criteria: * patients with normal fit result * patients younger than age 18
a study of md-7246 to treat abdominal pain in patients with diarrhea-predominant irritable bowel syndrome

Conditions: Irritable Bowel Syndrome With Diarrhea (IBS-D)

Summary: to evaluate the safety and tolerability, treatment effect on abdominal pain, and dose response of md-7246 administered orally to patients with diarrhea-predominant irritable bowel syndrome (ibs-d).


Eligibility criteria:
inclusion criteria: * patient meets the rome iv criteria for diagnosis of ibs-d * patient maintains a minimum level of compliance with daily diary * female patients of childbearing potential must agree to use one of the following methods of birth control: 1. hormonal contraception 2. double-barrier method 3. maintenance of a monogamous relationship with a male partner who has been surgically sterilized by vasectomy exclusion criteria: * patient has clinically significant findings on a physical examination and/or clinical laboratory tests * patient has symptoms of or been diagnosed with a medical condition that may contribute to abdominal pain * patient has a structural abnormality of the gastrointestinal (gi) tract or a disease or condition that can affect gi motility * patient has any protocol-excluded or clinically significant medical or surgical history that could confound the study assessments note: additional inclusion/exclusion criteria may apply

Keywords: abdominal pain diarrhea irritable bowel syndrome
comparison of two omeprazole-containing products for relief of frequent heartburn (mk-0764a-036)

Conditions: Heartburn

Summary: this study will evaluate a single ingredient product (omeprazole 20 mg) with a combination product capsule (omeprazole 20 mg + sodium bicarbonate 1100 mg) in participants with frequent heartburn.


Eligibility criteria:
inclusion criteria: * females of reproductive potential must demonstrate a negative urine pregnancy test and agree to use an acceptable method of birth control * suffer from frequent heartburn * refrain from taking non-study medicine or treatment for heartburn for the duration of the study * be free of any clinically significant disease that requires a physician's care * read and understand english exclusion criteria: * any significant medical condition which is a contraindication to the use of omeprazole or sodium bicarbonate * known hypersensitivity to the study drugs or any components * experiencing any of the following: trouble or pain with swallowing food, vomiting with blood, bloody or black stools * participation in another investigational study within 4 weeks prior to the screening visit.

Keywords: frequent heartburn omeprazole omeprazole, sodium bicarbonate drug combination gastrointestinal agents therapeutic uses pharmacologic actions enzyme inhibitors molecular mechanisms of pharmacological action proton pump inhibitors
role of maternal physical exercise on spontaneous labor onset

Conditions: Pregnancy; Labour Onset and Length Abnormalities

Summary: evaluate the effects of the practice of maternal physical exercise on the term of pregnancy as a method to enhance spontaneous labor.

at 38 weeks low-risk pregnant women, with singleton cephalic fetus and without previous cesarean delivery, were randomized into 2 groups: a control group without maternal physical exercise practice and a study group with 30 minutes of walking, 3 times a week at 4 km/h. induction of labor was performed at 41 weeks

Eligibility criteria:
inclusion criteria: * 38 weeks low-risk pregnant women * singleton cephalic fetus * without previous cesarean delivery exclusion criteria: * pathological pregnancy * twin pregnancy * previous cesarean section